Table 1

Demographic features, malignancy history, rheumatological, clinical and ultrasonographic manifestations, time to onset, autoantibody profile and treatment of the seven patients developing synovitis. Active synovitis was defined by the presence of power Doppler signal.

PtSexAge
(years)
Malignancy
(treatment)
Clinical manifestationsInterval
(weeks)
Autoantibody assessmentUSDiagnosisTreatment
1F55RCC
(nivolumab)
Simmetric polyarthritis3RF, ACPA,
ANA neg
Active synovitisRAPDN 12.5 mg/daily
2F61Melanoma
(nivolumab)
Simmetric polyarthritis3RF 22 UI/mL,
ACPA >300 UI/mL,
ANA+ (sp), a-SSA+
Active synovitisRAPDN 10 mg/daily
MTX 10 mg/weekly
3M68NSCLC
(nivolumab)
Monoartrhritis8RF, ACPA,
ANA neg
SynovitisUANSAIDs
4F72NSCLC
(nivolumab)
Polyarthritis18RF, ACPA,
ANA neg
SynovitisUAPDN 12.5 mg/daily
5M77NSCLC
(nivolumab)
Oligoarthritis4RF, ACPA,
ANA neg
SynovitisUANSAIDs
6M70NSCLC
(nivolumab)
Simmetric polyarthritis2RF, ACPA,
ANA neg
Active synovitisUAPDN 10 mg/daily
7M61NSCLC
(nivolumab)
Simmetric polyarthritis36RF, ACPA,
ANA neg
SynovitisUAPDN 10 mg/daily
  • ACPA, anti-citrullinated protein antibodies; ANA, anti-nuclear antibodies; a-SSA, anti-SSA; MTX, Methotrexate; NSAIDs, non-steroidal anti-inflammatory drugs; NSCLC, non-small cell lung cancer; PDN, prednisone; RA, rheumatoid arthritis; RCC, renal cell carcinoma; RF, rheumatoid factor; sp, Speckled; UA, undifferentiated arthritis; US, ultrasonographic.